1031 related articles for article (PubMed ID: 19909746)
41. Novel anti-inflammatory action of 5-aminoimidazole-4-carboxamide ribonucleoside with protective effect in dextran sulfate sodium-induced acute and chronic colitis.
Bai A; Yong M; Ma AG; Ma Y; Weiss CR; Guan Q; Bernstein CN; Peng Z
J Pharmacol Exp Ther; 2010 Jun; 333(3):717-25. PubMed ID: 20237071
[TBL] [Abstract][Full Text] [Related]
42. Physically crosslinked alginate/N,O-carboxymethyl chitosan hydrogels with calcium for oral delivery of protein drugs.
Lin YH; Liang HF; Chung CK; Chen MC; Sung HW
Biomaterials; 2005 May; 26(14):2105-13. PubMed ID: 15576185
[TBL] [Abstract][Full Text] [Related]
43. Loss of the tight junction protein ZO-1 in dextran sulfate sodium induced colitis.
Poritz LS; Garver KI; Green C; Fitzpatrick L; Ruggiero F; Koltun WA
J Surg Res; 2007 Jun; 140(1):12-9. PubMed ID: 17418867
[TBL] [Abstract][Full Text] [Related]
44. Targeting the proteasome: partial inhibition of the proteasome by bortezomib or deletion of the immunosubunit LMP7 attenuates experimental colitis.
Schmidt N; Gonzalez E; Visekruna A; Kühl AA; Loddenkemper C; Mollenkopf H; Kaufmann SH; Steinhoff U; Joeris T
Gut; 2010 Jul; 59(7):896-906. PubMed ID: 20581238
[TBL] [Abstract][Full Text] [Related]
45. Colon-targeted delivery of piceatannol enhances anti-colitic effects of the natural product: potential molecular mechanisms for therapeutic enhancement.
Yum S; Jeong S; Lee S; Nam J; Kim W; Yoo JW; Kim MS; Lee BL; Jung Y
Drug Des Devel Ther; 2015; 9():4247-58. PubMed ID: 26273188
[TBL] [Abstract][Full Text] [Related]
46. Bioefficacy of budesonide loaded crosslinked polyelectrolyte microparticles in rat model of induced colitis.
Crcarevska MS; Dodov MG; Petrusevska G; Gjorgoski I; Goracinova K
J Drug Target; 2009 Dec; 17(10):788-802. PubMed ID: 19938950
[TBL] [Abstract][Full Text] [Related]
47. Preparation and evaluation of carboplatin biodegradable polymeric nanoparticles.
Nanjwade BK; Singh J; Parikh KA; Manvi FV
Int J Pharm; 2010 Jan; 385(1-2):176-80. PubMed ID: 19854254
[TBL] [Abstract][Full Text] [Related]
48. Probing insulin's secondary structure after entrapment into alginate/chitosan nanoparticles.
Sarmento B; Ferreira DC; Jorgensen L; van de Weert M
Eur J Pharm Biopharm; 2007 Jan; 65(1):10-7. PubMed ID: 17101268
[TBL] [Abstract][Full Text] [Related]
49. The role of the complement and contact systems in the dextran sulfate sodium-induced colitis model: the effect of C1 inhibitor in inflammatory bowel disease.
Lu F; Fernandes SM; Davis AE
Am J Physiol Gastrointest Liver Physiol; 2010 Jun; 298(6):G878-83. PubMed ID: 20338925
[TBL] [Abstract][Full Text] [Related]
50. Clinicopathologic study of dextran sulfate sodium experimental murine colitis.
Cooper HS; Murthy SN; Shah RS; Sedergran DJ
Lab Invest; 1993 Aug; 69(2):238-49. PubMed ID: 8350599
[TBL] [Abstract][Full Text] [Related]
51. A vitamin D analogue inhibits colonic carcinogenesis in the AOM/DSS model.
Fichera A; Little N; Dougherty U; Mustafi R; Cerda S; Li YC; Delgado J; Arora A; Campbell LK; Joseph L; Hart J; Noffsinger A; Bissonnette M
J Surg Res; 2007 Oct; 142(2):239-45. PubMed ID: 17574271
[TBL] [Abstract][Full Text] [Related]
52. Mechanisms underlying the anti-inflammatory actions of boswellic acid derivatives in experimental colitis.
Anthoni C; Laukoetter MG; Rijcken E; Vowinkel T; Mennigen R; Müller S; Senninger N; Russell J; Jauch J; Bergmann J; Granger DN; Krieglstein CF
Am J Physiol Gastrointest Liver Physiol; 2006 Jun; 290(6):G1131-7. PubMed ID: 16423918
[TBL] [Abstract][Full Text] [Related]
53. Suppression of experimental colitis by intestinal mononuclear phagocytes.
Qualls JE; Kaplan AM; van Rooijen N; Cohen DA
J Leukoc Biol; 2006 Oct; 80(4):802-15. PubMed ID: 16888083
[TBL] [Abstract][Full Text] [Related]
54. Nonmyeloablative stem cell therapy enhances microcirculation and tissue regeneration in murine inflammatory bowel disease.
Khalil PN; Weiler V; Nelson PJ; Khalil MN; Moosmann S; Mutschler WE; Siebeck M; Huss R
Gastroenterology; 2007 Mar; 132(3):944-54. PubMed ID: 17383423
[TBL] [Abstract][Full Text] [Related]
55. Preparation and in vitro evaluation of mucoadhesive properties of alginate/chitosan microparticles containing prednisolone.
Wittaya-areekul S; Kruenate J; Prahsarn C
Int J Pharm; 2006 Apr; 312(1-2):113-8. PubMed ID: 16490331
[TBL] [Abstract][Full Text] [Related]
56. Pharmaceutical approaches to colon targeted drug delivery systems.
Chourasia MK; Jain SK
J Pharm Pharm Sci; 2003; 6(1):33-66. PubMed ID: 12753729
[TBL] [Abstract][Full Text] [Related]
57. Nanoparticles in inflammatory bowel disease: particle targeting versus pH-sensitive delivery.
Meissner Y; Pellequer Y; Lamprecht A
Int J Pharm; 2006 Jun; 316(1-2):138-43. PubMed ID: 16675176
[TBL] [Abstract][Full Text] [Related]
58. Efficacy of drugs used in the treatment of IBD and combinations thereof in acute DSS-induced colitis in mice.
Sann H; Erichsen Jv; Hessmann M; Pahl A; Hoffmeyer A
Life Sci; 2013 Apr; 92(12):708-18. PubMed ID: 23399699
[TBL] [Abstract][Full Text] [Related]
59. Reactivation of inflammatory bowel disease in a mouse model of depression.
Ghia JE; Blennerhassett P; Deng Y; Verdu EF; Khan WI; Collins SM
Gastroenterology; 2009 Jun; 136(7):2280-2288.e1-4. PubMed ID: 19272381
[TBL] [Abstract][Full Text] [Related]
60. Preparation and evaluation of nanoparticles made of chitosan or N-trimethyl chitosan and a cisplatin-alginate complex.
Cafaggi S; Russo E; Stefani R; Leardi R; Caviglioli G; Parodi B; Bignardi G; De Totero D; Aiello C; Viale M
J Control Release; 2007 Aug; 121(1-2):110-23. PubMed ID: 17601625
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
